<unk>  is a COX-2 selective inhibitor nonsteroidal anti-inflammatory drug. Its structure is different from that of other COX-2 inhibitors, such as celecoxib:<unk>  is an analogue of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid class of NSAIDs; it binds to a different site on the COX-2 enzyme than do other COX-2 inhibitors; it is the only acidic coxib and has the highest COX-2 selectivity of any NSAID. It was patented in 1997 and approved for medical use in 2003. It was manufactured by Novartis and is still sold in few countries, including Mexico, Ecuador and the Dominican Republic, under the trade name Prexige.<unk>  has been withdrawn from the market in several countries, mostly due to its potential for causing liver failure (sometimes requiring liver transplantation). It has never been approved for use in the United States.
Lumiracoxib
Valdecoxib
Deracoxib
Rofecoxib
Celecoxib
Etoricoxib
Parecoxib
Aceclofenac